Skip to main content
Clinical Trials/NL-OMON41854
NL-OMON41854
Completed
Not Applicable

A single-center, randomized, double-blind, placebo-controlled, single ascending dose study to investigate the pharmacokinetics, pharmacodynamic effects, safety and tolerability of single doses of RO5459072 in healthy volunteers. - RO5459072 Single Ascending Dose Study

F. Hoffmann-La Roche Ltd.0 sites16 target enrollmentTBD
ConditionsLupus10003816

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lupus
Sponsor
F. Hoffmann-La Roche Ltd.
Enrollment
16
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Healthy subjects
  • 18 and 60 years of age, inclusive
  • BMI 18 \- 30 kilogram/meter2
  • non smokers

Exclusion Criteria

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials